Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Laboratory of Diagnosis and Therapy of Lysosomal Disorders, |
RCV001578507 | SCV001547688 | likely pathogenic | Mucopolysaccharidosis, MPS-IV-A | 2021-02-01 | criteria provided, single submitter | curation | Splicing variant in canonical site (PVS1_very strong); absent from gnomAD v2.1.1 (PM2_moderate) |
Labcorp Genetics |
RCV001578507 | SCV004296418 | pathogenic | Mucopolysaccharidosis, MPS-IV-A | 2023-06-27 | criteria provided, single submitter | clinical testing | This sequence change affects an acceptor splice site in intron 4 of the GALNS gene. RNA analysis indicates that disruption of this splice site induces altered splicing and may result in an absent or disrupted protein product. For these reasons, this variant has been classified as Pathogenic. This variant disrupts a region of the GALNS protein in which other variant(s) (p.Trp520*) have been determined to be pathogenic (PMID: 24035930, 24726177). This suggests that this is a clinically significant region of the protein, and that variants that disrupt it are likely to be disease-causing. Studies have shown that disruption of this splice site results in skipping of exon 5 and introduces a premature termination codon (PMID: 9290256). The resulting mRNA is expected to undergo nonsense-mediated decay. ClinVar contains an entry for this variant (Variation ID: 1048402). This variant is also known as IVS 4(-1) G>A. Disruption of this splice site has been observed in individual(s) with clinical features of autosomal recessive mucopolysaccharidosis IVA (PMID: 9290256). This variant is not present in population databases (gnomAD no frequency). |
Molecular Biology Laboratory, |
RCV001578507 | SCV004012880 | association not found | Mucopolysaccharidosis, MPS-IV-A | no assertion criteria provided | research |